Want to see TSE:APTX full AI Analyst Report?
APTX Stock Chart & Stats
C$33.15
-C$0.18(-0.50%)
At close: 4:00 PM EDT
C$33.15
-C$0.18(-0.50%)
Day’s Range― - ―
52-Week RangeC$26.05 - C$40.18
Previous CloseN/A
Volume197.25K
Average Volume (3M)534.16K
Market Cap
C$7.69B
Enterprise ValueC$10.14K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)20.9
Beta-0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.18%
Share Statistics
EPS (TTM)N/A
Shares Outstanding228,499,020
10 Day Avg. Volume1,062,327
30 Day Avg. Volume534,162
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-11.21
Price to Sales (P/S)1.79
P/FCF Ratio13.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$40.75Price Target Upside22.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe shift from losses to solid profitability, alongside materially higher gross and EBIT margins, indicates stronger operating execution and earnings quality. If maintained, the improved margin structure can support reinvestment, absorb moderate revenue pressure, and strengthen cash generation over coming quarters.
Improving Cash GenerationStrong positive operating cash flow and sharply higher free cash flow provide tangible support for the earnings recovery. This cash generation gives Apotex resources to fund launches, pursue productivity initiatives, and reduce debt, although the current debt burden limits how quickly financial flexibility can improve.
Deep Launch Pipeline And Market PositionA multi-year pipeline with a meaningful expected revenue contribution creates visible avenues for product-led growth beyond existing portfolios. First-to-market launches and established Canadian strength can reinforce market position, diversify revenue sources, and support management’s FY27 growth outlook.
Bears Say
Highly Stressed Capital StructureDebt growth combined with negative shareholders’ equity materially reduces balance-sheet resilience and financial flexibility. Even with improving earnings and cash flow, the stressed structure can constrain investment, increase sensitivity to operating setbacks, and make deleveraging a central requirement for sustained stability.
U.S. And Specialty-generics WeaknessThe U.S. decline and sharper specialty-generics contraction show that revenue remains exposed to product-cycle comparisons and portfolio pressure. Loss of prior-year exclusivity benefits, combined with the ophthalmic pause, may weigh on near-term growth while new launches must replace eroding contributions.
Semaglutide Scaling And Competition RiskSemaglutide is an important growth opportunity, but constrained device and partner capacity could limit the company’s ability to convert demand into revenue. Expected competitor reentry may also reduce the durability of Apotex’s current sole-supplier position and pressure future market share.
APTX FAQ
What was Apotex Health Corp.’s price range in the past 12 months?
Apotex Health Corp. lowest stock price was C$26.05 and its highest was C$40.18 in the past 12 months.
What is Apotex Health Corp.’s market cap?
Apotex Health Corp.’s market cap is C$7.69B.
When is Apotex Health Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Apotex Health Corp.’s earnings last quarter?
Currently, no data Available
Is Apotex Health Corp. overvalued?
According to Wall Street analysts Apotex Health Corp.’s price is currently Undervalued.
Does Apotex Health Corp. pay dividends?
Apotex Health Corp. pays a Notavailable dividend of C$0.06 which represents an annual dividend yield of 0.18%. See more information on Apotex Health Corp. dividends here
What is Apotex Health Corp.’s EPS estimate?
Apotex Health Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apotex Health Corp. have?
Apotex Health Corp. has 228,499,020 shares outstanding.
What happened to Apotex Health Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Apotex Health Corp.?
Currently, no hedge funds are holding shares in TSE:APTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apotex Health Corp. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Apotex Health Corp.
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. It operates through three business lines including conventional generic pharmaceuticals; specialty generic pharmaceuticals; and brands & biosimilars. The company has a a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. Apotex Health Corp. was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC
APTX Stock 12 Month Forecast
Average Price Target
C$40.75
▲(22.93% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
CareRx
―
Medexus Pharmaceuticals Inc
―